Guarente, L., Sinclair, D. A., & Kroemer, G. (2024). Human trials exploring anti-aging medicines. Cell Metabolism, 36(2), 354–376. https://doi.org/10.1016/j.cmet.2023.12.007
https://www.cell.com/cell-metabolism/fulltext/S1550-4131(23)00458-8
QT:{{”
In a recent issue of Cell Metabolism, Guarente co-authored a review article about human trials exploring compounds that target pathways and mechanisms of aging along with David Sinclair, Ph.D., one of Dr. Guarente’s postdoctoral mentees and now a professor of genetics at Harvard Medical School, and Guido Kroemer, M.D., Ph.D., a professor at the Université Paris Cité. Guarente and his colleagues focus on eight drugs and compounds: metformin, NAD+ precursors, glucagon-like peptide-1 receptor agonists, TORC1 inhibitors, spermidine, senolytics, probiotics, and anti-inflammatories.
These interventions made the list for four reasons: 1) they’re well-represented in ongoing or completed human clinical trials; 2) they’ve been shown to slow aging in preclinical studies; 3) they’re thought to be sufficiently safe for long-term use in humans; and 4) they work by targeting the hallmarks of aging.
“}}
linkstream2 microblog 